129 related articles for article (PubMed ID: 38056855)
1. [Perioperative Rehabolotation Usefulness in Preventing Complications].
Usuda J
Kyobu Geka; 2023 Sep; 76(10):878-882. PubMed ID: 38056855
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease.
Azuma Y; Sano A; Sakai T; Koezuka S; Otsuka H; Tochigi N; Isobe K; Sakamoto S; Takai Y; Iyoda A
BMC Pulm Med; 2021 May; 21(1):174. PubMed ID: 34020622
[TBL] [Abstract][Full Text] [Related]
3. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
4. Preoperative management using inhalation therapy for pulmonary complications in lung cancer patients with chronic obstructive pulmonary disease.
Takegahara K; Usuda J; Inoue T; Ibi T; Sato A
Gen Thorac Cardiovasc Surg; 2017 Jul; 65(7):388-391. PubMed ID: 28281043
[TBL] [Abstract][Full Text] [Related]
5. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
7. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
[TBL] [Abstract][Full Text] [Related]
8. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
Liao PA; Pan SW; Chen CY; Deng CY; Dong YH
Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844
[TBL] [Abstract][Full Text] [Related]
9. Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline.
Mammen MJ; Pai V; Aaron SD; Nici L; Alhazzani W; Alexander PE
Ann Am Thorac Soc; 2020 Sep; 17(9):1133-1143. PubMed ID: 32530702
[No Abstract] [Full Text] [Related]
10. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA
Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
[TBL] [Abstract][Full Text] [Related]
11. Inhaled corticosteroids with combination inhaled long-acting beta
Tan DJ; White CJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD011600. PubMed ID: 27830584
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
13. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
14. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
16. A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD.
Lal C; Strange C
Expert Opin Pharmacother; 2017 Dec; 18(17):1833-1843. PubMed ID: 29115881
[TBL] [Abstract][Full Text] [Related]
17. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.
Calzetta L; Rogliani P; Matera MG; Cazzola M
Chest; 2016 May; 149(5):1181-96. PubMed ID: 26923629
[TBL] [Abstract][Full Text] [Related]
19. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
20. [Inhaled Triple Therapy in Severe Chronic Obstructive Pulmonary Disease (COPD)].
Gillissen A; Paparoupa M; Frings D; Atique B; Koczulla R
Pneumologie; 2018 Dec; 72(12):832-842. PubMed ID: 30153695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]